Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.5MCash on Hand
2.3mo Cash Runway
Follow MEDS by emailGet an email when MEDS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MEDS, unsubscribe in one click. Privacy
📣 What MEDS Says Is Next
fourth quarter · ““Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions,” said Gerald Commissiong, Interim Co-CEO of DataMEDS.”
Company press release, Nov 13, 2026 · SEC filing
Second Half 2026 · “Interim co-CEO Gerald Commissiong featured on Fox Business together with NFL Legend Emmitt Smith to discuss NFLAH support for Health Lives Here Expected Remaining Second Half 2026 Milestones”
Company press release, Aug 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Financing DataMeds AI filed a prospectus supplement for an at-the-market offering of up to $10,003,649 of common stock through Dawson James Securities as sales agent, with a 3.0% commission. The stock closed at $0.74 on November 13, 2026. Form 424B5 · SEC filing
Nov 16, 2026 ·
Financing DataMEDS AI entered an at-the-market sales agreement with Dawson James Securities allowing it to sell common stock through the agent from time to time. The Company pays a 3.0% commission on gross proceeds and is not obligated to make any sales. Form 8-K · SEC filing
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Q3 2026 revenue of $2.7 million rose 50% from $1.8 million in Q2, driven by Corexa Pharmacy dispensing. Company reported net profit of $10.535 million, or $2.72 per share, versus a loss in Q3 2025, and regained Nasdaq compliance. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Deal DataMEDS AI terminated its October 19, 2026 Second Amended and Restated Letter of Intent with Datavault AI, REBOOT Health AI, EOS Technology, Scilex and HealthBridge Advisors, citing market conditions. The company says no fees are owed and no shares will be issued under it. Form 8-K · SEC filing · Press release
Oct 26, 2026 ·
Deal DataMEDS signed a non-binding Second A&R LOI on Oct 19, 2026, to acquire QLPM IP from EOS and Scilex, expand its Datavault AI license, and take a controlling interest in Tollo Health. Target post-closing ownership: 89.5% held by counterparties. Definitive agreements are pending. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Listing DataMeds AI received a Nasdaq notice dated October 19, 2026 confirming it regained compliance with the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1). The company had reported stockholders' equity of $(12,447,801) in its 2025 annual report. Form 8-K · SEC filing · Press release
Oct 16, 2026 ·
Deal DataMeds signed an exclusive US license with REBOOT Health AI for GLP-1 direct-to-consumer use, issuing 666,667 shares plus a $50,000 payment and revenue sharing. Nasdaq flagged stockholders' equity of $(12,447,801) and the company is converting debt into stock. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
MEDS holds $2.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.2M/quarter from operations,
an estimated runway of 2.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 2 months +40
ATM program on file since Nov 2026 +15
Shelf registration (S-3, Apr 2026) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.10-Q, Nov 2026
Raised after last reported balance sheet (Oct 2026) -10
Share count 5,724,857 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MEDS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MEDS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.